The combination of pemetrexed and cisplatin appeared safe and effective in women with advanced, persistent or recurrent carcinoma of the cervix, according to results of a phase 2 trial. “This ...

The FDA this week approved pemetrexed in combination with cisplatin as first-line therapy for locally advanced metastatic non–small cell lung cancer in patients with nonsquamous history, according to ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best defensive stocks to buy, according to Steve Cohen. On September 7, the ...

The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm. The Food and Drug Administration (FDA) ...

The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not ...

Pemetrexed is an (antifolate) antineoplastic agent, prescribed for mesothelioma (cancer that develops from the protective lining of the internal tissues) and certain types of non-small cell lung ...

Learn everything you need to know about Pemetrexed-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer ...

Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: More Questions Than Answers Ramalingam et al 1 reported the results of a phase III trial, ECOG-ACRIN 5508, which compared ...

October 28, 2011 — The European Commission has approved pemetrexed (Alimta, Eli Lilly) for use as a single agent for "continuation maintenance" therapy in patients with advanced nonsquamous ...

Introduction: Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is increasing in frequency worldwide. Treatment options are limited, and response to chemotherapy is poor. The ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the Pemetrexed market was valued at US$ 2,062.5 million in 2017, and is projected to exhibit a CAGR of 1.3% over the forecast period ...